Monday, 16 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· February 17, 2026

Basilea erzielt starke Ergebnisse im Geschäftsjahr 2025 und übertrifft Umsatz- und Betriebsgewinn-Guidance

View original at globenewswire.com
“einschliesslich CHF 30.9 Mio. Umsatz aus Verträgen mit BARDA[1] (GJ 2024: CHF 10.2 Mio.) und CHF 4.3 Mio. Umsatz aus der Vereinbarung mit CARB-X[2] (GJ 2024: CHF 1.8 Mio.)”
Verbatim excerpt from the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cumulative positive cash flows of approximately CHF 600 million are expected from Cresemba and Zevtera over the next five-year period

    80% confidence
  • Cresemba generic competition could impact US market from Q4 2027 and European market from H2 2028

    80% confidence
  • Zevtera is expected to gain increasing momentum in the USA from Q2 2026

    80% confidence
  • Potential additional non-dilutive R&D funding of approximately USD 330 million from existing BARDA contracts may be allocated in further tranches

    80% confidence
  • Royalty revenues expected to rise to approximately CHF 120 million and milestone payments to CHF ~35 million in FY2026

    80% confidence

Cited in these Via News reports